Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine

Vaccine

Volumn 30, Issue 16, 2012, Pages 2647-2653

  Tomovici, A ^a   Barreto, L ^a   Zickler, P ^b   Meekison, W ^c   Noya, F ^d   Voloshen, T ^e   Lavigne, P ^a  

^a Sanofi Pasteur Limited   (Canada)

^b TASC Research Services   (Canada)

^c Westcoast Clinical Research   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e SANOFI PASTEUR   (France)

Author keywords

Pertussis; Serology; Vaccine

Indexed keywords

DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; TETANUS ANTIBODY;

ADAPTIVE IMMUNITY; ADOLESCENT; ADOLESCENT DISEASE; ADULT; ADULT DISEASE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DIPHTHERIA; FEMALE; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; PRIORITY JOURNAL; TETANUS;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, BACTERIAL; CHILD; DIPHTHERIA; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; TETANUS; VACCINES, COMBINED; WHOOPING COUGH;

EID: 84858279423     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.013     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention (CDC) Notifiable diseases and mortality tables. MMWR 2011, 59:1690-1717.
2. CDC Summary of notifiable diseases - United States, 2008. MMWR 2008, 77(54):1-94.
3. Advisory Committee on Immunization Practices Updated Recommendations for use of tetanus toxoid, diphtheria toxoid and acellular pertussis vaccine from the Advisory Committee on Immunization Practices 2010. MMWR 2011, 60:13-15.
4. CDC Summary of notifiable diseases - United States, 2005. MMWR 2005, 77(54):12.
5. Cherry J.D. The science and fiction of the resurgence of pertussis. Pediatrics 2003, 112:405-406.
6. Abu Sin M., Zenke R., Rünckendorf R., Littmann M., Jorgensen P., Hellebrand W. Pertussis outbreak in primary and secondary schools in Ludwigslust, Germany demonstrating the role of waning immunity. Pediatr Infect Dis J 2009, 28:242-244.
7. Edwards K.M. Overview of pertussis: focus on epidemiology, sources of infection, and long-term protection after infant vaccination. Pediatr Infect Dis J 2005, 24:S104-S108.
8. Centers for Disease Control and Prevention National, state, and local area vaccination coverage among adolescents 13-17 years - United States, 2009. MMWR 2010, 59:1018-1023.
9. Huberling D.L., Holman R.C., Paddock C.D., Murphy T.V. Infant and maternal risk factors for pertussis-related mortality in the United States, 1999-2004. Pediatr Infect Dis J 2009, 28:194-198.
10. Bisgard K.M., Pascual F.B., Ehresmann K.R., Miller C.A., Cianfrini C., Jennings C.E., et al. Infant pertussis: who was the source?. Pediatr Infect Dis J 2004, 23:985-989.
11. Schellekens J., von Konig C.H., Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J 2005, 24:S19-S24.
12. Kowalzik F., Prata Barbosa A., Fernandez V.R., Carvalho P.R., Avila-Aguero M.L., Goh D.Y.T., et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pedaitr Infect Dis J 2007, 26:238-242.
13. Wendelboe A.M., Njamkepo E., Bourillon A., Floret D., Gaudelus J., Gerber M., et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007, 26:293-299.
14. Cortese M.M., Baughman A.L., Zhang R., Srivastava Wallace G.S. Pediatric hospitalizations in the United States, 1993-2004. Pediatrics 2008, 121:484-926.
15. De Greef S.C., Mooi F.R., Weesterhof A., Verbakel N.N., Peeters M.F., Heuvelman C.J., et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 2010, 50:1339-1345.
16. Campinas-Marti M., Cherng H.K., Forsyth K., Guiso N., Halperin S., Huang L.-M., et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 2001, 20:641-646.
17. Forsyth K.D., Campins-Marti M., Caro J., Cherry J.D., Greenberg D., Guiso N., et al. New pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative. Clin Infect Dis 2004, 39:1802-1809.
18. Dylag A.M., Shah S.I. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit. Pediatrics 2008, 122:e550-e555.
19. Coudeville L., Van Rie A., Andre P. Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies. Epidemiol Infect 2008, 136:604-620.
20. Greenberg D.P., Doemland M., Bettinger J.A., Scheifele D.W., Halperin S.A. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine. Implications for disease prevention in the United States. Pediatr Infect Dis 2009, 28:521-528.
21. Edelman K.J., He Q., Makinen J.P., Haanpera M.S., Minh N.N.T., Schuerman L., et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis 2004, 39:179-185.
22. McIntyre P.B., Turnbull F.M., Egan A.M., Burgess M.A., Wolter J.M., Schuerman L.M. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine 2004, 23:380-385.
23. Edelman K., He Q., Makinen J., Sahlberg A., Haanpera M., Schuerman L., et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007, 44:1271-1277.
24. Barreto L., Guasparini R., Meekison W., Noya F., Young L., Mills E. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 2007, 25:8172-8179.
25. Halperin S.A., Smith B., Russell M., Hasselback P., Guasparini R., Skowronski D., et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine 2000, 18:1312-1319.
26. Halperin S.A., Smith B., Russell M., Scheifele D., Mills E., Hasselback P., et al. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J 2000, 19:276-283.
27. Galazka A.M. The immunological basis for immunization series, module 3: tetanus. Global programme for vaccines and immunization, expanded programme on immunization 1993, World Health Organization, Geneva.
28. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998, 16:1901-1906.
29. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16:1907-1916.